In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Hybrid Study Designs & the Link Between RWE, Epidemiology
A Q&A article in Outsourcing Pharma featuring commentary from Kerina Bonar, discussing the challenges and advantages of hybrid study designs. The article explores how designing studies with epidemiological input can be beneficial for real world evidence generation and ensuring a study design is fit for purpose.
-
FDA Guidance on Communicating with Payers
This year The Food and Drug Administration (FDA) released two final guidance documents. Learn more in this Scrip article about the most significant provisions of these documents and the key takeaways for manufacturers with respect to sharing health economic data with payers.
-
Digital Trials A Framework for Success
There is increasing interest in digital trials, that is the use of mHealth and mobile technology to capture insights outside the traditional clinical research setting. Discover more in this PME article.
-
Challenges Associated with new EU MDR and IVDR
Vicki Anastasi, and Karen Hill, ICON, examine the key challenges associated with the new EU MDR and IVDR in this article in Med-Tech Innovation News.
-
Using Economic Models to Gain Early Access
Early access schemes demand new ways of performing health economic evaluations. This means developing health economic models early to evaluate gaps and determine what level of investment makes sense. ICON's Nancy Risebrough and Mia Malmenas share insights in this Pharmafocus article.
-
Ready or Not, Medtech Braces For New EU Landscape
An article based on ICON’s session at the MedTech Conference in Philadelphia, featuring commentary from our expert, Vicki Anastasi, on preparations for the new EU Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) set to take effect in May 2020.
-
What ICER Pricing Would Mean for U.S. Drug Spend
The Institute for Clinical and Economic Review (ICER) is a major force in payer–manufacturer price negotiations. In a 2018 ICON plc survey of more than 20 U.S. payers, more than three quarters of respondents said that they would use an ICER cost-effectiveness threshold as a basis for negotiating a rebate contract. Read more from ICON's Nathan White, Adam Johns, and Eric Latch in the September 2018 issue of Managed Care.
-
CROs Must Be Aware Of Threat Posed By Big Tech
ICON’s CEO Steve Cutler discusses the impact of biotech funding and disruptive tech providers in this Scrip article.
-
Global Outsourcing Strategies
Colin Stanley, President, ICON Functional Services outlines how the market for outsourcing continues to grow including the types of outsourcing models sponsors have to choose from in this article in Contract Pharma.
-
The Path To A Successful Digital Trial
Transforming Clinical Trials: The Path To A Successful Digital Trial. A Thought Leadership article in Scrip Pharma Intelligence by Marie Mc Carthy, Senior Director Product Innovation, ICON and Chen Admati, Head of Intel Pharma Analytics Platform, Intel.
